NCT05037955

Completed

ILIT: Follow-up of Rhinitis Quality of Life

University of Zurich Source

Compare

Other study identifiers

Sponsor study identifier

2020-02369

Study Type

observational

Actual enrollment (reported)

162

Locations

1 country

Sites

1

Timeline

Study Start

February 1, 2021

Actual (reported)

Primary Completion

July 1, 2021

Actual (reported)

Study Completion

February 1, 2022

Actual (reported)

Brief Summary

Re-evaluation of patients treated with intralymphatic immunotherapy (ILIT) in terms of quality of life and therapeutic efficacy and comparison with subcutaneous immunotherapy (SCIT) 15 years post immunotherapy

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 162 participants
Study completion date: February 1, 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 1, 2021
Actual (reported)
Primary Completion
July 1, 2021
Actual (reported)
First Submitted
August 31, 2021
Actual (reported)
First Posted
September 8, 2021
Actual (reported)
Study Completion
February 1, 2022
Actual (reported)

Last Updated: March 23, 2022
Status Verified: March 2022
Last Update Submitted: March 22, 2022

Conditions

Allergic Rhinitis Due to Grass Pollen

Outcome Measures

Primary Outcomes (1)

Rhinoconjunctivitis quality of life
The standardised scoring of the outcomes "activities", "sleep", "non-nose/eye symptoms", "practical problems", "nasal symptoms", "eye symptoms", and "emotional" are entered in the form names "Rhinoconjunctivitis quality of life questionnaire with standardised activities (RQLQ)". The scoring is from 0 ("not troubled" or "none of the time") to 6 ("extremely troubled" or "all of the time").
February 2021 through June 2021

Study Arms (3)

ILIT from trial NCT00470457

Patients who received ILIT in the original trial in 2005

SCIT from trial NCT00470457

Patients who received SCIT in the original trial in 2005

SCIT outpatient control

Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Male and female patients with past or current hay fever due to grass pollen sensitisation. The patients received immunotherapy (SCIT or ILIT) in the NCT00470457 trials from 2005. A control group of patients received and completed SCIT as standard treatment of their hay fever at the Allergy Unit of the University Hospital Zurich during the last five years.

You may qualify if:

Receiving ILIT or SCIT treatment at the USZ.

Sponsors & Collaborators

University of Zurich
Otherlead

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Enrollment

162 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor, PhD

Study Record Dates

First Submitted

August 31, 2021

First Posted

September 8, 2021

Study Start

February 1, 2021

Actual (reported)

NCT01953471

Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)

Completed

NCT05297760

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

Phase 1/2Completed

NCT04700852

Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis

Not ApplicableUnknown

NCT04878237

Kinetics of Nasal Cytokine Responses to Mechanical Stimulation

Not ApplicableCompleted

NCT05191186

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

Phase 3Completed

NCT03290248

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Phase 1/2Completed

Indication: hay fever (type I sensitisation to grass pollen)

Adult male and female patients

Written/digital informed consent of the participating person

Complete return of both questionnaires

You may not qualify if:

Discontinuation of immunotherapy
Incomplete data set
Pathological barrier (e.g. dementia)
Language barrier (not understanding the German language)

Contact the study team to confirm eligibility.

Primary Completion

July 1, 2021

Actual (reported)

Study Completion

February 1, 2022

Actual (reported)

Last Updated

March 23, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05037955
Data provider: ClinicalTrials.gov
Source updated: 2022-03-23
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:06 UTC

Locations

CH(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

ILIT from trial NCT00470457

SCIT from trial NCT00470457

SCIT outpatient control

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations